GSK presents positive data for AREXVY, its respiratory syncytial virus (RSV) vaccine, indicating protection over three RSV ...

RSV is a highly contagious virus affecting the respiratory system, especially dangerous for infants, young children, and ...

Pfizer Inc. (NYSE:PFE) stock is trading higher with a session volume of 31.16 million as per data from Benzinga Pro. Activist ...

While recent CDC guidance threatens to shrink the market for a new class of immunizations, GSK continues to build the case ...

GSK said on Tuesday that its Arexvy respiratory syncytial virus vaccine was 43.3% effective in preventing severe illness in ...

Immunization appointments are now open for eligible Albertans. As of Monday (Oct. 7) both COVID-19 and influenza immunization ...

Illness from RSV is considered an infectious disease, usually leading to an infection of the upper respiratory tract but ...

Infections caused by the latest variant have symptoms including fever, chills, fatigue, cough, congestion and headache.

Cumulatively, data showed the shot to be 63% effective across the three-year period. However, efficacy appeared to wane and GSK said it expects revaccination will eventually be needed.

Respiratory Syncytial Virus RSV is a common respiratory virus primarily affecting young children Here are some remedies to ...

All infants are to be offered a vaccine against the respiratory syncytial (RS) virus from next year to cut the number of ...

Older people should take a new vaccine to protect them against Respiratory Syncytial Virus (RSV), according to new research ...